Genzyme Genetics Events

Oncology/Pathology

Recorded Webcast - KRAS: The Newly Recognized Central Biomarker for EGFR-Directed Therapy

KRAS activating mutations play a key role in neoplastic progression and are particularly prevalent in colorectal, pancreatic, and lung cancers. Recent studies have shown a significant correlation between KRAS mutations and non-response to targeted therapeutic agents for both NSCLC and colorectal adenocarcinoma.

The webcast on KRAS mutation analysis addresses the following questions:
-Why are KRAS mutations important?
-Where do they occur?
-What are the differences between KRAS mutations in NSCLC and CRC?
-What does it mean for treatment selection?
-What does it mean to the patient?

Presenter: Bruce C. Horten, M.D., Medical Director, Genzyme Genetics-New York

Register to view the recorded webcast.

Chemotherapy Foundation Symposium XXVI
New York, NY
November 5-7, 2008

CSP - California Society of Pathologists
Los Angeles, CA
December 3-6, 2008

ASH – American Society of Hematology
San Francisco, CA
December 6-8, 2008